Lantern Pharma Inc.

NASDAQ: LTRN · Healthcare · Biotechnology

PublicHQ Dallas, TX · DallasCIK 0001763950Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 27DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$17.1M

Employees

as of 2026-08-19

Market cap

$32.2M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$17.1M-$17.1M2025

Operating income-$18.0M-$18.0M2025

Total assets$11.0M$11.0M2025

Liabilities$4.5M$4.5M2025

Equity$6.5M$6.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Lantern Pharma Inc.’s financial profile?

Lantern Pharma Inc. earned -$17.1M in FY2025 net income.

Peers · Healthcare

BriaCell Therapeutics Corp.——Obsidian Therapeutics Inc.——MIRA Pharmaceuticals, Inc.——Estrella Immunopharma, Inc.——LeonaBio, Inc.——Sernova Corp.——

Neighbors

Dallas →

Caterpillar Inc.$67.6B80B+Texas Instruments Incorporated$17.7B86A AT&T Inc.$125.6B83B+McKesson Corporation$403.4B85A Energy Transfer LP$85.5B72B Strive, Inc. Variable Rate Series A Perpetual Preferred Stock$1.5M31D

Key facts

CEOPanna Sharma

SectorHealthcare

IndustryBiotechnology

HeadquartersDallas, TX

ExchangeNASDAQ: LTRN

Employees16

IPO date2020-06-11

Latest filings

8-K2026-08-14 10-Q2026-08-14 8-K2026-08-03 8-K2026-06-02 10-Q2026-05-15 8-K2026-05-15 8-K2026-05-14 8-K2026-04-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.